Fig. 2

cIAP2 expression is associated with sorafenib resistance in liver cancer. a-b HepG2 cells were first transfected with pcDNA3.1 or p-cIAP2, and then treated with sorafenib. c-d HepG2.215 cells were first transfected with control siRNA or cIAP2 siRNA, and then treated with sorafenib. Twenty-four h later, a and c the expression of cIAP2 and cleaved caspase-3 were measured by western blot, b and d cell viability was determined by MTT. For western blot, one representative data out of three is shown. For cell viability, data shown are mean ± SD of three independent experiments. ns, not statistically significant; *, p < 0.05; **, p < 0.01